Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 2.09
VAR's Cash to Debt is ranked higher than
69% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. VAR: 2.09 )
VAR' s 10-Year Cash to Debt Range
Min: 0.27   Max: 15.02
Current: 2.09

0.27
15.02
Equity to Asset 0.48
VAR's Equity to Asset is ranked higher than
57% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. VAR: 0.48 )
VAR' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.57
Current: 0.48

0.34
0.57
F-Score: 5
Z-Score: 5.43
M-Score: -2.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.73
VAR's Operating margin (%) is ranked higher than
93% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. VAR: 18.73 )
VAR' s 10-Year Operating margin (%) Range
Min: 8.1   Max: 22.67
Current: 18.73

8.1
22.67
Net-margin (%) 13.24
VAR's Net-margin (%) is ranked higher than
90% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. VAR: 13.24 )
VAR' s 10-Year Net-margin (%) Range
Min: -4.1   Max: 15.36
Current: 13.24

-4.1
15.36
ROE (%) 23.96
VAR's ROE (%) is ranked higher than
97% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. VAR: 23.96 )
VAR' s 10-Year ROE (%) Range
Min: -6.52   Max: 33.66
Current: 23.96

-6.52
33.66
ROA (%) 11.76
VAR's ROA (%) is ranked higher than
92% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. VAR: 11.76 )
VAR' s 10-Year ROA (%) Range
Min: -2.75   Max: 17.33
Current: 11.76

-2.75
17.33
ROC (Joel Greenblatt) (%) 72.33
VAR's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. VAR: 72.33 )
VAR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 16.63   Max: 162.99
Current: 72.33

16.63
162.99
Revenue Growth (%) 9.80
VAR's Revenue Growth (%) is ranked higher than
83% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. VAR: 9.80 )
VAR' s 10-Year Revenue Growth (%) Range
Min: -27.1   Max: 17.4
Current: 9.8

-27.1
17.4
EPS Growth (%) 3.60
VAR's EPS Growth (%) is ranked higher than
76% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. VAR: 3.60 )
VAR' s 10-Year EPS Growth (%) Range
Min: -58.1   Max: 112.3
Current: 3.6

-58.1
112.3
» VAR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

VAR Guru Trades in Q4 2013

Ray Dalio 39,598 sh (+7.28%)
Charles Brandes 129,772 sh (+6.18%)
David Rolfe 2,279,191 sh (+4.91%)
Westport Asset Management 285,000 sh (unchged)
Robert Karr 305,000 sh (unchged)
Louis Moore Bacon Sold Out
John Hussman Sold Out
Joel Greenblatt 45,154 sh (-0.95%)
Jeremy Grantham 140,763 sh (-8.97%)
First Pacific Advisors 129,700 sh (-26.1%)
Steven Cohen 19,139 sh (-29.6%)
Paul Tudor Jones 5,311 sh (-92.94%)
» More
Q1 2014

VAR Guru Trades in Q1 2014

Caxton Associates 32,000 sh (New)
John Hussman 150,000 sh (New)
Jeremy Grantham 261,431 sh (+85.72%)
David Rolfe 2,455,154 sh (+7.72%)
CI Can Am Small Cap 74,000 sh (unchged)
Westport Asset Management 285,000 sh (unchged)
Robert Karr Sold Out
Charles Brandes 129,412 sh (-0.28%)
First Pacific Advisors 127,600 sh (-1.62%)
Joel Greenblatt 38,427 sh (-14.9%)
Ray Dalio 29,598 sh (-25.25%)
Paul Tudor Jones 3,500 sh (-34.1%)
Steven Cohen 3,692 sh (-80.71%)
» More
Q2 2014

VAR Guru Trades in Q2 2014

Joel Greenblatt 88,471 sh (+130.23%)
Paul Tudor Jones 4,800 sh (+37.14%)
Jeremy Grantham 291,831 sh (+11.63%)
David Rolfe 2,601,412 sh (+5.96%)
Charles Brandes 135,989 sh (+5.08%)
First Pacific Advisors 127,600 sh (unchged)
John Hussman Sold Out
Caxton Associates Sold Out
Ray Dalio Sold Out
Westport Asset Management 277,500 sh (-2.63%)
» More
Q3 2014

VAR Guru Trades in Q3 2014

John Hussman 20,000 sh (New)
David Rolfe 2,832,194 sh (+8.87%)
Charles Brandes 146,016 sh (+7.37%)
First Pacific Advisors 127,600 sh (unchged)
Westport Asset Management 277,500 sh (unchged)
Joel Greenblatt Sold Out
Jeremy Grantham 266,531 sh (-8.67%)
Paul Tudor Jones 4,100 sh (-14.58%)
» More
» Details

Insider Trades

Latest Guru Trades with VAR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-09-30 New Buy0.14%$80.89 - $87.52 $ 87.754%20000
Joel Greenblatt 2014-09-30 Sold Out 0.09%$80.89 - $87.52 $ 87.754%0
John Hussman 2014-06-30 Sold Out 0.94%$78.66 - $84.85 $ 87.757%0
Joel Greenblatt 2014-06-30 Add 130.23%0.05%$78.66 - $84.85 $ 87.757%88471
Ray Dalio 2014-06-30 Sold Out 0.02%$78.66 - $84.85 $ 87.757%0
Robert Karr 2014-03-31 Sold Out 1.6%$77.34 - $84.96 $ 87.757%0
John Hussman 2014-03-31 New Buy0.94%$77.34 - $84.96 $ 87.757%150000
Ray Dalio 2014-03-31 Reduce -25.25%0.01%$77.34 - $84.96 $ 87.757%29598
John Hussman 2013-12-31 Sold Out 0.41%$72.5 - $79.84 $ 87.7516%0
Robert Karr 2013-09-30 New Buy1.7%$66.3 - $76.27 $ 87.7522%305000
John Hussman 2013-09-30 New Buy0.41%$66.3 - $76.27 $ 87.7522%100000
Andreas Halvorsen 2013-09-30 Sold Out 0.12%$66.3 - $76.27 $ 87.7522%0
Charles Brandes 2013-09-30 New Buy0.12%$66.3 - $76.27 $ 87.7522%122218
Ray Dalio 2013-09-30 Reduce -39.25%0.01%$66.3 - $76.27 $ 87.7522%36912
Andreas Halvorsen 2013-06-30 New Buy0.12%$64.02 - $72.78 $ 87.7528%317605
Ray Dalio 2013-06-30 Add 38.63%0.01%$64.02 - $72.78 $ 87.7528%60756
Mario Gabelli 2013-06-30 Sold Out $64.02 - $72.78 $ 87.7528%0
John Hussman 2013-03-31 Sold Out 0.25%$68.66 - $75.25 $ 87.7521%0
Joel Greenblatt 2013-03-31 Add 65.73%0.07%$68.66 - $75.25 $ 87.7521%47672
Ray Dalio 2013-03-31 New Buy0.03%$68.66 - $75.25 $ 87.7521%43827
John Hussman 2012-12-31 Reduce -46.8%0.17%$57.08 - $72.35 $ 87.7532%133000
Joel Greenblatt 2012-12-31 Reduce -33.84%0.06%$57.08 - $72.35 $ 87.7532%28764
Mario Gabelli 2012-12-31 Reduce -30.95%$57.08 - $72.35 $ 87.7532%5355
John Hussman 2012-09-30 Reduce -80%1.12%$53.73 - $61.76 $ 87.7550%250000
Andreas Halvorsen 2012-09-30 Sold Out 0.18%$53.73 - $61.76 $ 87.7550%0
Joel Greenblatt 2012-09-30 Add 130.72%0.1%$53.73 - $61.76 $ 87.7550%43476
Andreas Halvorsen 2012-06-30 New Buy0.18%$57.15 - $68.81 $ 87.7539%359900
Joel Greenblatt 2012-06-30 New Buy0.08%$57.15 - $68.81 $ 87.7539%18844
Ray Dalio 2012-06-30 Sold Out 0.04%$57.15 - $68.81 $ 87.7539%0
Ray Dalio 2012-03-31 New Buy0.04%$64.48 - $71.7 $ 87.7538%40865
Ray Dalio 2011-12-31 Sold Out 0.15%$50.1 - $67.13 $ 87.7548%0
Joel Greenblatt 2011-12-31 Sold Out 0.09%$50.1 - $67.13 $ 87.7548%0
Ray Dalio 2011-09-30 Add 4192.44%0.15%$49.63 - $71.36 $ 87.7549%191400
Joel Greenblatt 2011-09-30 New Buy0.09%$49.63 - $71.36 $ 87.7548%10401
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Varian Medical Systems Inc

David Rolfe Comments on Varian Medical Systems - Apr 18, 2014

Varian Medical Systems (VAR) has been a staple in our portfolio since the fall of 2005. The stock has rebounded smartly, up +31% from its April 2013 lows through the first quarter. Varian continues to be the global market share and technological leader in the radiation oncology business. Unfortunately, the incidence of cancer continues its deadly growth. In the U.S. alone, the American Cancer Society projects that some 1.7 million people will be diagnosed with cancer. Expectations of new cancer cases around the world are approaching 25 million over the next three decades. Of these new cases, approximately two-­‐thirds will be treated with some sort of radiation therapy. Varian has been at the forefront of linear particle accelerator since the late 1940's. Today the Company's installed base numbers over 7,300 LINACS across the globe – a 60% market share. As impressive as that may sound, the availability of state-­‐of-­‐the-­‐art radiation therapy (radiosurgery and proton therapy) outside of the U.S. is woefully low. The developed world has access to 35 to 110 LINACS per million people over the age of 65. In the U.S., it's 110 LINACS per million. Western Europe and Japan is 35 to 65 per million. In India, Africa, Eastern Europe and Southeast Asia there are between 1 and 20 machines per million. In China there is less than 10 machines per million. Complementing the Company's long-­‐term growth opportunity in radiation therapy is the secular trend in the "digitization of radiology," which is a key driver of their lucrative software and flat-­‐panel services business, plus their X-­‐ray tube replacement business that sells into the installed base of competing LINACS. The Company's initiatives to drive greater productivity continue to bear fruit. In 2013 sales per employee increased 14% and operating income per employee increased 20% over 2012 levels. Such productivity has helped the Company offset the continuing losses as they rollout their proton therapy machines. Cutting edge technologies such as proton therapy are one of the many reasons why cancer survivorship rates are up to nearly 70% from 50% from just the 1970's. You will be hearing much more about the marvels of proton therapy in the years to come. The key benefit of proton therapy over the latest x-­‐ray technology is that proton beams, due to proton's relatively larger sub-­‐atomic mass, can be controlled and stopped at the tumor. Conventional X-­‐rays particles cannot be 3 stopped and risk damaging surrounding healthy cells. Due to the exceptional accuracy of a proton beam, the oncologist can more safely deliver much higher doses of radiation (hypofraction), which kills cancer faster with fewer treatments. Furthermore, tumors that are close to vital organs are ideal for proton therapy. These include head and neck, breast, lung, gastrointestinal, prostate and spine. Proton therapy is also ideal for children to avoid longer-­‐term side effects of traditional radiation therapy. The advantages of this therapy have been known since the 1940's, but the cost of commercialization has been a nearly insurmountable hurdle. The Varian proton therapy equipped facility at the Scripps Proton Therapy center in San Diego just went online in January. This $220 million, 102,000 square-­‐foot, facility is only the 15th proton therapy facility in the U.S. At its core sits a 95-­‐ton superconducting cyclotron where the proton beam is generated using oxygen and hydrogen to create a plasma stream. Protons are then extracted and accelerated to roughly 100,000 miles per second. Such miracles of science and technology (Cincinnati Children's Hospital just recently placed a proton order) come at considerable costs. The Company needs to get the costs of such systems below $25 million in order to drive any meaningful growth and profitability from proton therapy. Given Varian's long and exceptional history of innovation with LINACS, combined with proton therapy's high barriers to entry, we believe the Company is well-­‐positioned to eventually reap a substantial proportion of any potential financial rewards generated by this ground-­‐breaking technology. Stericycle continued its steady streak of growth. Last quarter earnings per share were up 12%, driven by a 13% increase in revenues, compared to the December 2012 calendar quarter. Stericycle is able to methodically deliver such growth through a unique combination of organic and inorganic means. For instance, during the quarter they closed eight acquisitions that will generate roughly $34 million in incremental annual revenues. As for the Company's competitive positioning, the regulated medical waste industry market opportunity is roughly $10.5 billion spread across a highly fragmented competitive field, consisting of regional or local players, with none generating revenues above $100 million.

From David Rolfe (Trades, Portfolio)'s Wedgewood Partners first quarter 2014 commentary.

Check out David Rolfe latest stock trades

Top Ranked Articles about Varian Medical Systems Inc

David Rolfe Comments on Varian Medical Systems
Varian Medical Systems (VAR) has been a staple in our portfolio since the fall of 2005. The stock has rebounded smartly, up +31% from its April 2013 lows through the first quarter. Varian continues to be the global market share and technological leader in the radiation oncology business. Unfortunately, the incidence of cancer continues its deadly growth. In the U.S. alone, the American Cancer Society projects that some 1.7 million people will be diagnosed with cancer. Expectations of new cancer cases around the world are approaching 25 million over the next three decades. Of these new cases, approximately two-­‐thirds will be treated with some sort of radiation therapy. Varian has been at the forefront of linear particle accelerator since the late 1940's. Today the Company's installed base numbers over 7,300 LINACS across the globe – a 60% market share. As impressive as that may sound, the availability of state-­‐of-­‐the-­‐art radiation therapy (radiosurgery and proton therapy) outside of the U.S. is woefully low. The developed world has access to 35 to 110 LINACS per million people over the age of Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 22.90
VAR's P/E(ttm) is ranked higher than
89% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 106.60 vs. VAR: 22.90 )
VAR' s 10-Year P/E(ttm) Range
Min: 12.14   Max: 44.19
Current: 22.9

12.14
44.19
P/B 5.60
VAR's P/B is ranked higher than
61% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. VAR: 5.60 )
VAR' s 10-Year P/B Range
Min: 3.06   Max: 11.34
Current: 5.6

3.06
11.34
P/S 3.03
VAR's P/S is ranked higher than
71% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. VAR: 3.03 )
VAR' s 10-Year P/S Range
Min: 1.63   Max: 5.96
Current: 3.03

1.63
5.96
EV-to-EBIT 15.02
VAR's EV-to-EBIT is ranked higher than
91% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. VAR: 15.02 )
VAR' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 28.3
Current: 15.02

6.9
28.3
PEG 5.45
VAR's PEG is ranked higher than
90% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VAR: 5.45 )
VAR' s 10-Year PEG Range
Min: 0.77   Max: 2.96
Current: 5.45

0.77
2.96
Shiller P/E 24.53
VAR's Shiller P/E is ranked higher than
93% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VAR: 24.53 )
VAR' s 10-Year Shiller P/E Range
Min: 15.58   Max: 80.16
Current: 24.53

15.58
80.16
Current Ratio 2.08
VAR's Current Ratio is ranked higher than
64% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. VAR: 2.08 )
VAR' s 10-Year Current Ratio Range
Min: 1.42   Max: 2.33
Current: 2.08

1.42
2.33
Quick Ratio 1.60
VAR's Quick Ratio is ranked higher than
65% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. VAR: 1.60 )
VAR' s 10-Year Quick Ratio Range
Min: 1.13   Max: 1.87
Current: 1.6

1.13
1.87

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 975.00
VAR's Price/Net Current Asset Value is ranked higher than
73% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VAR: 975.00 )
VAR' s 10-Year Price/Net Current Asset Value Range
Min: 26.73   Max: 902.22
Current: 975

26.73
902.22
Price/Tangible Book 6.58
VAR's Price/Tangible Book is ranked higher than
69% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.57 vs. VAR: 6.58 )
VAR' s 10-Year Price/Tangible Book Range
Min: 0.88   Max: 10.47
Current: 6.58

0.88
10.47
Price/DCF (Projected) 1.52
VAR's Price/DCF (Projected) is ranked higher than
92% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VAR: 1.52 )
VAR' s 10-Year Price/DCF (Projected) Range
Min: 1.1   Max: 3.11
Current: 1.52

1.1
3.11
Price/Median PS Value 0.98
VAR's Price/Median PS Value is ranked higher than
82% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. VAR: 0.98 )
VAR' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 1.46
Current: 0.98

0.69
1.46
Price/Peter Lynch Fair Value 2.96
VAR's Price/Peter Lynch Fair Value is ranked higher than
95% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VAR: 2.96 )
VAR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.93   Max: 2.74
Current: 2.96

0.93
2.74
Price/Graham Number 2.56
VAR's Price/Graham Number is ranked higher than
84% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VAR: 2.56 )
VAR' s 10-Year Price/Graham Number Range
Min: 0.51   Max: 3.64
Current: 2.56

0.51
3.64
Earnings Yield (Greenblatt) 6.70
VAR's Earnings Yield (Greenblatt) is ranked higher than
91% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. VAR: 6.70 )
VAR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 14.5
Current: 6.7

3.5
14.5
Forward Rate of Return (Yacktman) 10.73
VAR's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 349 Companies
in the Global Medical Devices industry.

( Industry Median: 0.59 vs. VAR: 10.73 )
VAR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 11.3   Max: 49.1
Current: 10.73

11.3
49.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:VNM.Germany
Varian Medical Systems Inc is a Delaware corporation was originally incorporated in 1948 as Varian Associates, Inc. The Company is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. It is a supplier of x-ray imaging components for medical, scientific, and industrial applications and also supplies x-ray imaging products for cargo screening and industrial inspection. The Company has two reportable operating segments: Oncology Systems and X-ray Products. The Oncology Systems business segment designs, manufactures, sells and services hardware and software products for treating cancer with radiotherapy, stereotactic radiotherapy, stereotactic body radiotherapy, stereotactic radiosurgery and brachytherapy. Products include linear accelerators, brachytherapy afterloaders, treatment simulation and verification equipment and accessories; as well as information management, treatment planning and image processing software. Oncology Systems products enable radiation oncology departments in hospitals and clinics to perform conventional radiotherapy treatments and offer advanced treatments such as fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy and stereotactic radiotherapy, as well as to treat patients using brachytherapy techniques, which involve temporarily implanting radioactive sources. The Companys Oncology Systems products are also used by neurosurgeons to perform stereotactic radiosurgery. Oncology Systems customers worldwide include university research and community hospitals, private and governmental institutions, healthcare agencies, physicians offices and cancer care clinics. The X-ray Products business segment designs, manufactures, sells and services x-ray imaging components for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, special procedures, computed tomography and industrial applications. The Companys x-ray imaging components are sold to large imaging system OEM customers that incorporate them into their medical diagnostic, dental, veterinary and industrial imaging systems. It sells x-ray tubes and flat panel digital image detectors for filmless x-ray imaging to small OEMs, independent service companies and directly to end-users for replacement purposes. The Company has three other businesses that are reported together under the Other category. SIP designs, manufactures, sells and services Linatron x-ray accelerators, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The VPT business develops, designs, manufactures, sells and services products and systems for delivering proton therapy, a form of external beam radiotherapy using proton beams for the treatme
» More Articles for VAR

Headlines

Articles On GuruFocus.com
No More a Simple Distributor Sep 07 2014 
Bearish Investor John Hussman's 5 Top New Stock Buys May 02 2014 
David Rolfe Comments on Varian Medical Systems Apr 18 2014 
David Rolfe's Wedgewood Partners Q1 2014 Investor Letter Apr 18 2014 
David Rolfe's Wedgewood Partners Fourth Quarter 2013 Client Letter Jan 22 2014 
comment on VAR Mar 03 2013 
Wedgewood Partners' David Rolfe Comments on Varian Medical Systems Nov 12 2012 
Weekly CFO Sells Highlight: CMCSA, MM, PIR, VAR, SPRT Nov 03 2012 
Introducing New Guru David Rolfe, Added to EXPD, CTSH, VAR, QCOM in Q2 Sep 04 2012 
simple business high Feb 24 2012 


More From Other Websites
Final Glance: Health Care Equipment companies Nov 21 2014
Final Glance: Health Care Equipment companies Nov 21 2014
Early Glance: Health Care Equipment companies Nov 21 2014
Early Glance: Health Care Equipment companies Nov 21 2014
Midday Glance: Health Care Equipment companies Nov 20 2014
Midday Glance: Health Care Equipment companies Nov 20 2014
Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto Nov 20 2014
Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto Nov 20 2014
Varian Medical (VAR) Down to Strong Sell on Dismal Q3 Nov 14 2014
Varian Medical Systems to Highlight the Latest Digital Detectors and X-ray Tubes at the MEDICA 2014... Nov 12 2014
Varian Medical Systems to Highlight the Latest Digital Detectors and X-ray Tubes at the MEDICA 2014... Nov 12 2014
New Cancer Center at Guy's Hospital in London to be Equipped with Varian TrueBeam Treatment Machines Nov 11 2014
New Cancer Center at Guy's Hospital in London to be Equipped with Varian TrueBeam Treatment Machines Nov 11 2014
Varian Medical Systems CEO Dow Wilson Appointed to the President's Advisory Council on Doing... Nov 06 2014
Varian Medical Systems CEO Dow Wilson Appointed to the President's Advisory Council on Doing... Nov 06 2014
Doctors at Innovative Cancer Institute in Miami Use New Radiosurgery System to Treat Tumor... Oct 29 2014
GenesisCare Commences Cancer Treatments Using Queensland's First TrueBeam Medical Linear Accelerator... Oct 27 2014
Varian Medical Systems Misses on Q4 Earnings and Revenues Oct 23 2014
UK's NHS Supply Chain Selects 10 TrueBeam Treatment Machines to Enable More Advanced Cancer... Oct 23 2014
UK's NHS Supply Chain Selects 10 TrueBeam Treatment Machines to Enable More Advanced Cancer... Oct 23 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK